Analytical Data
-
Gene name
HLA-A*03:01&B2M&KRAS G12C(VVVGACGVGK) Monomer
- Application
-
Alternative Names
HLA-A*0301 & B2M & KRASG12C (VVVGACGVGK)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
NP_002107.3 (G25-T305)&P61769
-
Expression Region
NP_002107.3 (G25-T305)&P61769 (I21-M119)&VVVGACGVGK
-
Molecular Weight
66 kDa, 55 kDa, 41-43 kDa, 34 kDa, 27 kDa and 11 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*03:01/B2M/KRAS G12C (VVVGACGVGK) monomeric recombinant protein focuses on the interactions between human leukocyte antigen (HLA), beta-2-microglobulin (B2M), and mutated KRAS protein, which is a critical component of various malignancies, particularly pancreatic and colorectal cancers. KRAS G12C is a common mutation that leads to aberrant signaling pathways, promoting uncontrolled cell growth and survival. Understanding the immune response to this specific mutant peptide, presented by the HLA-A*03:01 molecule, is essential for developing targeted immunotherapies. The recombinant protein allows for the investigation of T-cell recognition and binding affinity, providing insights into how the immune system can be harnessed to set off a therapeutic response against KRAS-driven tumors. This research not only elucidates the intricacies of antigen presentation but also aids in the design of vaccines and personalized treatments that can enhance anti-tumor immunity, thereby improving clinical outcomes for patients with KRAS G12C-associated cancers.
